Perspective Therapeutics Inc. (CATX)
CATX trades on NYSE in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2023-12-31, https://www.sec.gov/Archives/edgar/data/728387/000143774924009696/0001437749-24-009696-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2023-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | CATX on NYSE |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000728387 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2023
| Line | Value |
|---|---|
| Revenue | $1.4M |
| Net income | -$46.5M |
| Operating income | -$40.9M |
| Net margin | -3243.2% |
| Operating margin | -2855.0% |
| Revenue growth | No prior-year revenue to compare |
| Cash | $9.2M |
| Total assets | $97.9M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 77.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 10-Q 2026-11-09 |
| Cash and burn | $41.0M cash; operating cash flow -$27.0M a quarter. | Report 2026-09-30 |
| Shares outstanding | 120,758,815 (2026-11-04); 74,337,990 a year earlier; 280,571,026 three years earlier. 3y figure adjusted for split (1-for-10 overall). | Cover page 2026-11-04 |
| Reverse splits, 3 years | 1; latest 1-for-10 on 2024-06-17 | Source 2024-06-17 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the market | Latest 2026-02-03 |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | WithumSmith+Brown, PC, San Francisco, California, United States | PCAOB Form AP 2026-03-19 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $42K, sold $1.3M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q1 2027 2026-09-30 | Not filed | -$32.4M | -$31.4M | $41.0M | $1.6M | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2026 2026-06-30 | Not filed | -$26.8M | -$20.6M | $48.5M | $1.6M | Needs four quarters | 10-Q 2026-11-09 |
| Q3 2026 2026-03-31 | Not filed | -$26.2M | -$31.5M | $54.0M | $1.6M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2026 2025-12-31 | Not filed | -$37.5M | -$24.7M | $30.6M | $1.6M | Needs four quarters | 10-K 2026-03-16 |
| Q1 2026 2025-09-30 | Not filed | -$26.0M | -$16.3M | $26.8M | $1.6M | Needs four quarters | 10-Q 2026-11-09 |
| Q4 2025 2025-06-30 | Not filed | -$21.5M | -$20.0M | $28.8M | $1.7M | Needs four quarters | 10-Q 2026-11-09 |
| Q3 2025 2025-03-31 | Not filed | -$18.2M | -$21.6M | $44.4M | $1.7M | Needs four quarters | 10-Q 2026-11-09 |
| Q2 2025 2024-12-31 | Not filed | -$40.2M | -$26.6M | $61.6M | $1.7M | Needs four quarters | 10-K 2026-03-16 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2026-02-03 |
| Latest annual report | 10-K | 2026-03-16 |
| Latest quarterly / interim | 10-Q | 2026-11-09 |
| Latest current report | 8-K | 2026-11-09 |
| Latest proxy | DEFA14A | 2026-04-16 |
Source: SEC EDGAR submissions feed, 1,004 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | +11.9% |
| 1 month | -58.6% |
| 3 months | -69.7% |
| Year to date | -65.8% |
| 1 year | -54.6% |
| From 52-week high | -83.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| OKUR | OnKure Therapeutics Inc. | $2.75 | +4.56% | $111.4M |
| PDSB | PDS Biotechnology Corporation | $0.9241 | +5.90% | $113.4M |
| NERV | Minerva Neurosciences Inc | $2.20 | -4.35% | $109.6M |
| IMUX | Immunic Inc. | $7.23 | -3.86% | $114.8M |
| FHTX | Foghorn Therapeutics Inc. | $1.79 | -13.53% | $107.3M |
| BGM | BGM Group Ltd. | $8.01 | +1.71% | $107.0M |
| ADAG | Adagene Inc. | $1.60 | -6.43% | $105.7M |
| UPB | Upstream Bio Inc. | $2.15 | -22.66% | $117.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier